[Clinical value of percutaneous ethanol ablation in complicated renal carcinoma]

To probe clinical value of percutaneous ethanol ablation (PEA) in complicated renal carcinoma.

10 cases complicated renal carcinoma patients with 16 lesions ranged from 1.7-8.4 cm totally, renal cancer in 7 cases, renal hamartoma in 3 cases,underwent CT guided percutaneous ethanol ablation (PEA) by local anesthesia Plain and contrast CT scan was adopted to evaluate clinical effect and make follow-up.

Each patient accepted 2 times PEA in average with follow-up time ranged from 2 to 26 months averaged in 18 months. No recurrence was seen in 1 case isolated renal patient unfortunately with renal cancer through 1 year and 9 months follow-up after 2 times PEA. The other isolated renal cancer patient died of acute renal failure after 4 times PEA. Lesions were fully ablated in 2 cases renal cancer patients with low back pain and blood urine and symptoms disappeared after PEA accordingly. Other 3 cases renal cancer patients went through 1 year and 6 months, 2 years and 2 months, and 1 year follow-up respectively. 1 case died of distant metastasis and 2 cases kept stabilization evaluated by CT scan. Hemorrhage within lesions disappeared in 2 cases renal hamartoma after just one time PEA, which kept stabilization through 1 year, 1 year and 10 months follow-up respectively. 1 case hamartoma patient gave up treatment after 2 times PEA. No complications including urinary fistula, hemorrhage, intestinal perforation and needle track implantation were seen in all patients.

CT guided PEA is a microinvasive, positive curative effect and facultative method in treating complicated renal carcinomas. But for isolated renal patient with renal cancer,PEA should be performed cautiously.